William Dall’Acqua
William Dall’Acqua supervises a group in the Department of Antibody Discovery and Protein Engineering, R&D at AstraZeneca.
His team of 29 scientists is working on the discovery of new therapeutic antibody drugs and establishing novel antibody technology platforms. In particular, William’s group has developed a novel and ground-breaking strategy to improve the serum half-life of human IgG. Such long-lasting molecules have the potential to make an impact in the field of antibody-based therapy.
William has been studying protein structure, function and engineering for over 20 years and has co-authored over 45 papers and one book chapter in the field. He has also been named inventor on 16 issued patents. He has Bachelor and Masters’ Degrees in Biochemistry from the University of Paris, and a PhD in Immunology from the University of Paris in conjunction with the University of Maryland. He also spent two and a half years as a postdoctoral fellow at Genentech’s Molecular Oncology Department, before joining AstraZeneca.
Extending the half-life of antibodies
As soon as we got the early data, it was clear the YTE platform was very robust. We ended up improving the antibody half life by up to 2-4 times.
LATEST PROJECT
The YTE leap in technology
POSITION
Head, Antibody Lead Generation, Gaithersburg
PEER RECOGNITION
Elsevier publication co-editor, peer publication reviewer, NIH site reviewer, panellist, SAB member and speaker at multiple conferences
Featured publications
Enhancement of antibody-dependent cell-mediated cytotoxicity
Borrok MJ, Luheshi NM, Beyaz N et al. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding. MAbs. 2015 4; 7(4):743-51.
Structural Insights into Sifalimumab
Oganesyan V, Peng L, Woods RM, Wu H, Dall'Acqua WF. Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab. J Biol Chem. 2015; 290(24):14979-85.
Molecular basis of bispecific antibody's target selectivity
Mazor Y, Hansen A, Yang C et al. Insights into the molecular basis of a bispecific antibody's target selectivity. MAbs. 2015; 7(3):461-9.
Improving target cell specificity
Mazor Y, Oganesyan V, Yang C et al. Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs. 2015; 7(2):377-89.
Antagonistic activity of anifrolumab
Peng L, Oganesyan V, Wu H, Dall'Acqua WF, Damschroder MM. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. MAbs. 2015; 7(2):428-39.
FcRn affinity threshold that governs IgG recycling
Borrok MJ, Wu Y, Beyaz N et al. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J Biol Chem. 2015 ; 290(7):4282-90.
It is an amazing feeling to see something you've worked on in the lab make it to patients and make a difference.
Our people
Our people share a common purpose: to push the boundaries of science to deliver life-changing medicines.
What science can do
Stories from our people and our partners reveal the passion, energy and knowledge that enable us to put science at the heart of everything we do.
Our company
We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
Join AstraZeneca
and help us deliver life-changing medicines
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.